Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

How antiviral pill molnupiravir shot ahead in the COVID drug hunt

The Merck pill, which could become the first oral antiviral COVID treatment, forces the SARS-CoV-2 coronavirus to mutate itself to death.
  1. Cassandra Willyard
    View author publications

    You can also search for this author in PubMed  Google Scholar

The pharmaceutical firm Merck announced last week that an antiviral pill it’s developing can cut hospitalizations and deaths among people with COVID-19 by half. The results haven’t yet been peer reviewed. But if the drug candidate, molnupiravir, is authorized by regulators, it would be the first oral antiviral treatment for COVID-19. By contrast, the other currently authorized drugs must be delivered intravenously or injected.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-021-02783-1

Updates & Corrections

  • Clarification 09 October 2021: This story was updated to clarify that the two Indian drugmakers testing a generic version of molnupiravir did so independently of Merck, and to add comments from Merck indicating that moderate cases of COVID-19 in India are defined as being more severe than those in the United States.

References

  1. Beigel, J. H. et al. N. Engl. J. Med. 383, 1813-1826 (2020).

    Google Scholar 

  2. Sheahan, T. P. et al. Sci. Transl. Med. 12, eabb5883 (2020).

    Google Scholar 

  3. Cox, R. M. et al. Nature Microbiol. 6, 11-18 (2021).

    Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links